In Part 2 of the ASCO 2026 Highlights series, hosts Dr. Narjust Florez and Dr. Stephen Liu are joined by Dr. Julie Brahmer and Dr. Solange Peters to discuss some of the most notable immunotherapy advances presented at the 2026 ASCO Annual Meeting. The conversation explores emerging data for PD-1/VEGF and PD-L1/VEGF bispecific antibodies, the growing role of antibody-drug conjugates in combination with immunotherapy, and promising new strategies targeting KRAS-mutant lung cancers, highlighting how these approaches may reshape the future treatment landscape.

Guests:

Julie R. Brahmer, MD, MSc, FASCO, FAIO

The Marilyn Meyerhoff Professor of Thoracic Oncology

Co-Leader, Cancer Immunology Research Program

Co-Director, Upper Aerodigestive Cancers Program

Director, Johns Hopkins Kimmel Cancer Center, Bayview Campus

Professor Solange Peters, MD, PhD

Chair of Medical Oncology

Director of Oncology Department - CHUV

Lausanne University Hospital

In this Part 1 of 2 ASCO 2026 Highlights episodes, hosts Dr. Narjust Florez and Dr. Stephen Liu are joined by Dr. Alice Shaw and Dr. Jonathan Goldman to review some of the most impactful targeted therapy data presented at the 2026 ASCO Annual Meeting. The discussion explores the practice-changing LIBRETTO-432 trial in early-stage RET-positive NSCLC, long-term outcomes with lorlatinib in ALK-positive disease, emerging data for neladalkib, and promising results for sunvozertinib in EGFR exon 20 insertion–positive NSCLC, highlighting how these findings may influence treatment decisions across disease stages.

Guests:

Dr. Alice Shaw. is a Professor of Medicine at Harvard Medical School, Chair of Medical Oncology, and a thoracic oncologist at Dana Farber Cancer Institute. She is widely recognized as a pioneer in the field of ALK-positive non-small cell lung cancer, having led landmark clinical trials that established crizotinib, ceritinib, and lorlatinib as standards of care.

Dr. Jonathan W. Goldman is a Professor of Medicine and thoracic oncologist at the UCLA David Geffen School of Medicine, where he serves as a principal investigator in the Phase I drug development program. Dr. Goldman has been at the forefront of early-phase oncology trials across multiple tumor types, with a particular focus on novel therapeutics in lung cancer, and he was the presenting author of Libretto 432 at the plenary session at the 2026 ASCO

In this episode of Lung Cancer Considered, host Dr. Narjust Florez is joined by Natalie Brown and Dr. Aurora Lucas to explore how patients and caregivers are using artificial intelligence in the context of lung cancer care. The discussion highlights real-world experiences, addressing both the benefits of AI in improving understanding and empowerment, and the risks of misinformation, overreliance, and lack of personalization. The conversation also offers practical guidance for patients, families, and clinicians on using AI responsibly while reinforcing the importance of partnership with the care team.

Guests:

Aurora Lucas, EdD

Lung Cancer Patient Advocate

Natalie S. Brown, MBA

Lung Cancer Advocate & Speaker

Founder, Beyond The Diagnosis LLC

As part of IASLC’s ongoing series of podcasts in world languages, Dr. Alfredo Addeo moderates a Virtual Tumor Board discussion with Dr. Andrea Fillipi and Dr. Piergiorgio Solli. The tumor board focuses on the management of resectable EGFR-mutant NSCLC.

Host: • Alfredo Addeo, MD

Head of Oncology Service

University Hospital Geneva

Guests:

Andrea R. Filippi, MD

Head of Radiation Oncology, Fondazione Istituto Nazionale dei Tumori, Milan

Associate Professor, Radiation Therapy

Department of Oncology, University of Milan

Piergiorgio Solli, MD, PhD

Head of Thoracic Surgery

IRCCS Fondazione Istituto Nazionale dei Tumori, Milan

In this episode of Lung Cancer Considered, host Dr. Stephen Liu discusses KRAS updates from the American Association for Cancer Research (AACR) 2026 Annual Meeting with Dr. Deborah Doroshow, Dr. David S. Hong, and Dr. Jonathan Riess.

Guests:

Deborah Doroshow, MD, PhD

Associate Professor of Medicine, Hematology/Oncology

Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai

David S. Hong, MD

Douglas E. Johnson Endowed Professor

Deputy Chair, Department of Investigational Cancer Therapeutics [A Phase I Program]

Division of Cancer Medicine

Clinical Medical Director, Clinical and Translational Research Center

The University of Texas MD Anderson Cancer Center

Jonathan Riess, MD

Associate Professor of Medicine, UC Davis Comprehensive Cancer Center

Director of Thoracic Oncology, University of California, Davis

This episode of Lung Cancer Considered, part of IASLC’s World Language Series, features host Dr. Narjust Florez leading a Spanish-language discussion with Dr. José Corona-Cruz and Dr. Diego Carrillo on perioperative chemoimmunotherapy in early-stage lung cancer. Using a real-world case, they explore clinical decision-making, biomarker considerations, and surgical challenges, with a focus on implementation barriers in Latin America. The conversation highlights multidisciplinary strategies and practical insights to optimize care in resource-variable settings.

This episode of LCC covers the work of our nursing and allied health professional committee and, most importantly, highlight their role in the care of patients with thoracic malignancies.

Guests:

Professor Nicole Kiss is a Fellow of Dietitians Australia and Clinical Associate Professor in the Institute for Physical Activity and Nutrition at Deakin University. Nicole co-leads the Exercise and Nutrition for Cancer research group, with her research focused on early identification of cancer-related muscle loss and improving access to treatment.

Dr. Morten Quist is a former IASLC Board member and is currently an Associate Professor and Research Physiotherapist at the University Hospital of Copenhagen, Rigshospitalet. For the past 25 years, he has pioneered clinical exercise-based rehabilitation for people living with cancer, with a primary focus on exercise, prehabilitation, and rehabilitation in lung cancer. His work bridges research, clinical care, patient advocacy, and voluntary engagement – always with patient wellbeing at the center.

This episode of Lung Cancer Considered covers lung cancer in India and brings awareness about its first and largest advocacy group in the nation. To learn more about Lung Connect India, key members of the team will share how the organization began and the work they have done to improve the care of patients with lung cancer in the region.

Guest:

Vandana Mahajan, Lead Counselor for Lung Connect India, brings a unique and inspiring voice shaped by her dedication to supporting patients and families affected by lung cancer, and her commitment to driving conversations that matter from prevention and early detection to treatment advances and survivorship.

Sanjeev Sharma, the Director & CEO of Lung Connect India, an initiative dedicated to improving awareness, access, and advocacy in lung cancer care. With a strong commitment to patient-centered innovation, he works to bridge gaps between patients, caregivers, clinicians, and policymakers, advancing meaningful dialogue and practical solutions to improve lung cancer outcomes

As part of IASLC’s ongoing podcast series in world languages, Dr. Chul Kim moderates a discussion in Korean with Dr. Beung-Chul Ahn and Dr. Hyein Jeon. The session focuses on the clinical management of EGFR-mutant non-small cell lung cancer (NSCLC) through a case-based discussion.

Guests:

In this episode, recorded in Mandarin, host Dr. Chunxia Su leads a discussion about early stage and preoperative care for patients with NSCLC with an EGFR mutation.

Guests:

Wenzhao Zhong, Deputy Prensendent of Guangdong Provincial People's Hospital, Director of the Cancer Institute, Guangdong Provincial People's Hospital

Jie Hu， Deputy director, Department of Respiratory Medicine, Shanghai Geriatric Medical Center，Zhongshan Hospital, Fudan University

Min Fan M D， Deputy Director , Department of Radiation Oncology, Fudan University Shanghai Cancer Center